Skip to main content
. 2018 May 22;9(39):25586–25596. doi: 10.18632/oncotarget.25387

Figure 2. Immunological response - IFNγ and Granzyme B ELISPOT.

Figure 2

Peripheral blood mononuclear cells were collected from all subjects at baseline, 6 weeks, 12 weeks, and 24 weeks and evaluated for antigen-specific IFNγ or granzyme B secretion by ELISPOT. (A) Shown are immune responses to PAP protein or peptide library, PSA peptide library (non-specific control), and tetanus (positive control) for patients grouped by study arm. A positive antigen-specific response was defined as a statistically significant response (compared with media control) that was at least 3-fold over the baseline value and with a frequency of at least 1/100,000 cells. Red squares indicate positive responses, black indicates no response, and white indicates no data. (B) Shown are individual ELISPOT data for the three individuals (two from Arm 1 – 10004 and 10006, and one from Arm 2 – 20006) who exhibited PAP-specific immunity at all post-treatment time points in panel A.